Nano- and Microcap Stocks

  • neu auf watch .0003

    Sylios Corp. (PC) (UNGS)

    UNGS 6 Month Chart

    [Blocked Image:]…-greater-cannabis-company


    Sylios Corp Increases Authorized Share Repurchase Plan

    Download PDF

    ST. PETERSBURG, FL / ACCESSWIRE / May 22, 2015 / Sylios Corp (PINKSHEETS: UNGS), a holding corporation with operations engaged in the exploration and development of oil and natural gas properties, real estate development, equity investments and the development of products utilized for the medical and recreational marijuana industry announced today that its Board of Directors has approved an increase to its January 2011 Share Repurchase Plan.

    On May 21, 2015, the Board of Directors of the Company voted, at the request of Management, and approved an increase and extension to the January 11, 2011 Share Repurchase Plan. The Company was previously authorized to repurchase up to Two Hundred Fifty Thousand No/100 Dollars ($250,000) of its common stock in the open market or in privately negotiated transactions. The Company is now authorized to repurchase up to Five Hundred Thousand and NO/100 Dollars ($500,000) for a period of two years from the date of the May 21, 2015 resolution. The repurchase program will be funded by the Company's available cash and may be commenced or suspended at any time or from time to time. The plan will continue as long as periodic management reviews determine it to be fiscally feasible and may be discontinued at any time.

    Certain covenants within the Company's previously issued Convertible Notes limited the amount and timing of shares available to be purchased under the Share Repurchase Plan. Now that these Convertible Notes have been retired, the Company's options for repurchases have been expanded.

  • neu auf watch…I&ei=LOxuVan-F83FsAHO9YMQ


    Our authorized capital consists of 750,000,000 shares of common stock, par value $0.001 per share. As of the date of this Report and after giving effect to the Acquisition, 63,879,270 shares of our common stock were issued and outstanding.


    viel platz für dilution. cash bestand sagt das wird auch kommen.

    As of November 30, 2014, we had $12,565 in cash and cash equivalents and total assets, $195,864 in total liabilities, a working capital deficit of $115,494 and an accumulated deficit of $324,042


  • LFAP

    LifeApps is a digital media company focusing on health, fitness, sports publications, and next-generation social networks. The company is a leading, authorized developer, publisher and licensee for Apple iOS iPhone, iPod Touch, and iPad and Android tablets on Google Play and Kindle Fire and Androids via Amazon Mobile Marketplace. Health, fitness and sports enthusiasts can benefit from the expertise of top-tier sports physicians, performance fitness trainers and professional athletes through LifeApps multi-sport and fitness publications and mobile apps. These subject matter experts create the skills, drills and workouts that are featured in the family of LifeApps Digital Media products and publications.

    For more information about LifeApps, please visit:


    Common stock, $0.001 par value, 300,000,000 shares authorized, 124,866,731 and 91,530,000 shares issued and outstanding, as of March 31, 2015

    As of May 15, 2015 there were issued and outstanding 140,466,731 shares of Common Stock

    moderate dilution im quartal, einfach gesagt, infolge ceo hat in firma gebuttert und bekommts wieder zurück:

    On March 25, 2015, we entered into a debt conversion agreement (the “Agreement”) with our Chief Executive Officer, Robert Gayman. Pursuant to the terms of the Agreement, we agreed to convert $31,250 in loans made to us by Mr. Gayman into 25,000,000 restricted shares of our common stock (the “Conversion Shares”). The conversion price used to calculate the number of Conversion Shares was set at $0.0020833 based on the following formula: the conversion price will be equal to the lesser of $0.068 or 60% of the lowest trade price in the 25 trading days prior to the conversion.

    On March 25, 2015, our Board of Directors approved the conversion of up to $200,000 in amounts owed to Mr. Gayman for advances made to us and salary not paid to him, in accordance with the provisions of the Agreement. As of that date, Mr. Gayman had made loans to us in the aggregate amount of $95,377, for working capital purposes, and we owed Mr. Gayman $174,750 in accrued and unpaid salary.

    rest sieht übersichtlich und nicht toxisch aus.

    chart sieht nicht schlecht aus, scheint konsolidiert zu haben zwischen 002-3


    09/17/2014 - - LifeApps Digital Media Inc. (OTCQB: LFAP) ("LifeApps"), an emerging growth company and designer of applications ("apps"), new media, products and next-generation social networks for sports, health, fitness and entertainment enthusiasts and operator of wholesale sporting goods e-tail supplier Sports One Group and Performance Gear proudly announces that former President and CEO of Sony Computer Entertainment America LLC has joined the LifeApps Advisory Board.

    Tretton as one of the founding members of the Playstations executive team, played a pivotal role in making all PlayStation platforms best sellers in the U.S., Canada and Latin America, including the successful launches of PS One, PlayStation2, PSP (PlayStationPortable), PlayStation3, PlayStationVita, PlayStationNetwork, and PlayStation4, which first launched in North America on November 15, 2013. He joined in 1995 held the role of President and CEO from 2006 until leaving to pursue other ventures in April of 2014. During his tenure, Tretton has also been responsible for achieving several industry milestones, including surpassing 50 million units of the PlayStation2 in North America and most recently, selling more than one million PS4 units in 24 hours following the launch in North America.

    "LifeApps has developed a nice library of impressive health, fitness, lifestyle medicine and sports applications," states Mr. Tretton. "Joining the Advisory Board at LifeApps is a fantastic opportunity to work with an emerging growth company developing business strategies and revenue models within the rapidly evolving digital distribution and new media mobile applications market."

    "We are extremely pleased to welcome Jack Tretton to LifeApps," stated Robert Gayman, CEO of LifeApps. "Jack brings a wealth of business and digital technology experience and inspiration to our team and will be an important part of moving LifeApps into exciting new digital opportunities."

    Prior to joining Sony Computer Entertainment America, Tretton worked for JVC Musical Industries, an international publisher of videogames, where he served as general manager directing the company's sales, product development, marketing, finance and operation efforts. From 1986 to 1991, Tretton held numerous high ranking positions, including vice president of sales with Activision, an international publisher of interactive software. He also held marketing research and sales positions with Majers Corporation and Duracell, U.S.A.

    Mr. Tretton also stated about joining LifeApps, "Exciting new markets and business models are forming from the convergence of advanced mobile technologies, always-on mobile internet connectivity, and innovative new approaches to app capabilities."


    anhang LII. der erste kauf 350k is von mir, dann sieht man ein 400k bid 0.0025 is meins..


  • b00n hat am 03.06.2015 - 14:02 folgendes geschrieben:

    hab gesehen, es gehn paar newsletter dazu rum.. vlt gibts doch n runchen vorm crash..

  • bei LFAP wurd ich gestern nicht mehr ganz gefüllt, kamen von den gewünschten 400k nur 51k dazu. somit sinds aktuell 401k im bunker.

    hab wieder ein bid drin, 329k stk zu 0027.

    mal schauen obs heut klappt.

  • b00n hat am 04.06.2015 - 14:37 folgendes geschrieben:


    bei LFAP wurd ich gestern nicht mehr ganz gefüllt, kamen von den gewünschten 400k nur 51k dazu. somit sinds aktuell 401k im bunker.

    hab wieder ein bid drin, 329k stk zu 0027.

    mal schauen obs heut klappt.

    so, posi wurde eben gefüllt.

  • b00n hat am 04.06.2015 - 15:48 folgendes geschrieben:


    b00n hat am 04.06.2015 - 14:37 folgendes geschrieben:

    so, posi wurde eben gefüllt.

    420k bid @ 0024 reingestellt...

  • der stoff aus dem pinkis gemacht sind..

  • b00n hat am 05.06.2015 - 21:18 folgendes geschrieben:


    heut sind ein paar 23 dazugekommen..

    posi mittlerweile auf 1.290.200 stk angewachsen, ep 25

    bid auf 24 drin

    gestern erneut 23er zugelegt, 1.700.000 stk ep 24 sinds nun.

  • b00n hat am 30.06.2015 - 16:08 folgendes geschrieben:


    b00n hat am 09.06.2015 - 14:55 folgendes geschrieben:

    die party beginnt

    100% wären bereits drin gelegen in der ersten "bounceverdächtigen zuckung" , ich denke es wird hier nochn schöner "deppenrun" kommen, könnte gut 0.005 - 0.012 erreichen.

    sso, ich hab nu meine hausaufgaben gemacht und bin mal im garten unter den bäumen in meiner hamaca.. schönes weekend allen jungs und mädels..

  • TSOI on the move!

    Therapeutic Solutions International, Inc.

    July 09, 2015 08:30 ET
    Therapeutic Solutions International Files Patent on Cancer Immune Modulation Using Its ProJuvenol™ Product

    Company Explores Enhancing Efficacy of Existing Oncology Immunotherapeutics by Nutraceutical Intervention

    OCEANSIDE, CA--(Marketwired - Jul 9, 2015) - Therapeutics Solutions International, Inc., (OTC PINK: TSOI) announced today the filing of a patent application covering the use of its ProJuvenol™ product, as well as various pterostilbene compositions, for use in augmenting efficacy of existing immuno-oncology drugs that are currently on the market. The patent is based on the ability of pterostilbene, one of the major ingredients of ProJuvenol™, to reduce oxidative stress produced by cancer cells, which in turn protects the immune system from cancer mediated immune suppression.

    "Immuno-Oncology, described by Science Magazine as 'Breakthrough of the Year1' offers the possibility of not only killing tumor cells in a non-toxic manner, but also establishing immunological memory, which patrols the body and destroys recurrent tumor cells. While great progress has been made in developing drugs that stimulate the immune system to recognize and kill tumors, a major pitfall of current approaches is that tumors produce chemicals and oxidative stress that suppresses the immune system, thus limiting efficacy of immune therapies," said Timothy Dixon, CEO of Therapeutics Solutions International, Inc.

    Pterostilbene, which is chemically related to resveratrol, has been published to possess anticancer2,3, antioxidant4, and anti-inflammatory activities5. Through the filing of the recent patent, the company is exploring whether its lead product, ProJuvenol™, may be useful as a nutraceutical adjuvant to conventional cancer immunotherapies.

    Timothy Dixon, CEO of TSOI, added, "The importance of proper nutrition in the context of immunotherapy cannot be overstated. Studies on one of the original cancer immunotherapies, interleukin-2, demonstrated that efficacy was related to anti-oxidant content in the patients at time of therapy6. Accordingly, we are seeking through the current work to identify whether our currently marketed product, ProJuvenol™, may be utilized as part of an integrative approach to building up the immune response of cancer patients."

    1 Couzin-Frankel J. Breakthrough of the year 2013. Cancer immunotherapy. Science. 2013;342:1432-3.
    2 Yang et al. Pterostilbene exerts antitumor activity via the Notch1 signaling pathway in human lung adenocarcinoma cells. PLoS One. 2013 May 3;8(5):e62652.
    3 Li et al. Pterostilbene acts through metastasis-associated protein 1 to inhibit tumor growth, progression and metastasis in prostate cancer. PLoS One. 2013;8(3):e57542.
    4 McCormack and McFadden. A review of pterostilbene antioxidant activity and disease modification. Oxid Med Cell Longev. 2013;2013:575482.
    5 Qureshi et al. Inhibition of nitric oxide and inflammatory cytokines in LPS-stimulated murine macrophages by resveratrol, a potent proteasome inhibitor. Lipids Health Dis. 2012 Jul 10;11:76.
    6 Marcus et al. Severe hypovitaminosis C occurring as the result of adoptive immunotherapy with high-dose interleukin 2 and lymphokine-activated killer cells. Cancer Res. 1987 Aug 1;47(15):4208-12.

    About Therapeutic Solutions International, Inc.
    The Company's corporate website is Our new products can be viewed on and products can be ordered at

    These Supplement products have not been evaluated by the United States Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any diseases.